Free Trial
NASDAQ:XERS

Xeris Biopharma (XERS) Stock Price, News & Analysis

Xeris Biopharma logo
$7.89 +0.05 (+0.64%)
Closing price 04:00 PM Eastern
Extended Trading
$7.74 -0.15 (-1.89%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Xeris Biopharma Stock (NASDAQ:XERS)

Key Stats

Today's Range
$7.77
$7.97
50-Day Range
$4.66
$7.99
52-Week Range
$2.48
$8.03
Volume
1.40 million shs
Average Volume
2.54 million shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.08
Consensus Rating
Moderate Buy

Company Overview

Xeris Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

XERS MarketRank™: 

Xeris Biopharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 293rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Xeris Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about Xeris Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xeris Biopharma is -37.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xeris Biopharma is -37.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Xeris Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    8.27% of the outstanding shares of Xeris Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently decreased by 26.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Xeris Biopharma does not currently pay a dividend.

  • Dividend Growth

    Xeris Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.27% of the outstanding shares of Xeris Biopharma have been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 5.4.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently decreased by 26.73%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Xeris Biopharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.
  • Search Interest

    19 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xeris Biopharma insiders have sold 1,206.65% more of their company's stock than they have bought. Specifically, they have bought $109,500.00 in company stock and sold $1,430,777.00 in company stock.

  • Percentage Held by Insiders

    Only 4.56% of the stock of Xeris Biopharma is held by insiders.

  • Percentage Held by Institutions

    42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xeris Biopharma's insider trading history.
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XERS Stock News Headlines

Did you spot this in the Oval Office last week?
When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust.tc pixel
See More Headlines

XERS Stock Analysis - Frequently Asked Questions

Xeris Biopharma's stock was trading at $3.39 at the beginning of the year. Since then, XERS stock has increased by 132.7% and is now trading at $7.89.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million.
Read the conference call transcript
.

Xeris Biopharma (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma's top institutional investors include Geode Capital Management LLC (2.33%), Qube Research & Technologies Ltd (1.91%), Rosalind Advisors Inc. (1.33%) and Legal & General Group Plc (1.12%). Insiders that own company stock include Paul R Edick, Kevin Mcculloch, John Patrick Shannon Jr, Beth Hecht, John Johnson and Dawn Halkuff.
View institutional ownership trends
.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/07/2025
Today
9/04/2025
Next Earnings (Estimated)
11/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XERS
CIK
1867096
Fax
N/A
Employees
290
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$4.00
Potential Upside/Downside
-10.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.21)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$54.84 million
Net Margins
-13.01%
Pretax Margin
-14.36%
Return on Equity
N/A
Return on Assets
-8.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.95
Quick Ratio
1.24

Sales & Book Value

Annual Sales
$203.07 million
Price / Sales
6.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-65.79

Miscellaneous

Outstanding Shares
161,480,000
Free Float
154,117,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
0.13

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:XERS) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners